Active substance

Results for the substance lumacaftor ivacaftor

5 results

About this active substance

The combination of lumacaftor and ivacaftor is used for the treatment of cystic fibrosis in patients with specific CFTR gene mutations. It improves CFTR protein function, reducing disease symptoms.

The medication is taken orally, usually twice daily, and should be taken with fat-containing food to enhance absorption. It is important to follow the treatment regimen prescribed by the doctor.

Side effects may include headaches, nausea, diarrhea, or upper respiratory tract infections. In rare cases, elevated liver enzymes or allergic reactions may occur.

This combination is not recommended for patients with severe liver impairment or those with hypersensitivity to any of the medication's components.